Whole genome scanning as a cytogenetic tool in hematologic malignancies

Blood

Volumn 112, Issue 4, 2008, Pages 965-974

  Maciejewski, Jaroslaw P ^a   Mufti, Ghulam J ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; GENOME; GENOTYPE; HEMATOLOGIC MALIGNANCY; HETEROZYGOSITY; HUMAN; KARYOTYPE; LABORATORY TEST; METAPHASE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; UNIPARENTAL DISOMY; BLOOD DISEASE; CHROMOSOME ANALYSIS; GENETICS; GENOMICS; METHODOLOGY; REVIEW;

CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; GENOMICS; HEMATOLOGIC NEOPLASMS; HUMANS;

EID: 51649103380     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-130435     Document Type: Article

References (79)

1. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial: The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
2. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336.
3. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385-4395.
4. Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol. 2001;73:429-437.
5. Sole F, Luno E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 2005; 90:1168-1178.
6. Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood. 1992;80:1825-1831.
7. Licht JD. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene. 2001;20:5660-5679.
8. Shigesada K, van de SB, Liu PP. Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11. Oncogene. 2004;23: 4297-4307.
9. de TH, Lavau C, Marchio A, et al. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675-684.
10. de TH, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 1990;347:558-561.
11. Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol. 2005;23:6339-6344.
12. Liebisch P, Dohner H. Cytogenetics and molecular cytogenetics in multiple myeloma. Eur J Cancer. 2006;42:1520-1529.
13. Van Den NE, Robin V, Francart J, et al. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. Leukemia. 2007;21:1715-1722.
14. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007;25:799-804.
15. Tiu R, Gondek L, O'Keefe C, Maciejewski JP. Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia. 2007;21:1648-1657.
16. de JH. Visualizing DNA domains and sequences by microscopy: a fifty-year history of molecular cytogenetics. Genome. 2003;46:943-946.
17. Evers C, Beier M, Poelitz A, et al. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del (5q) using oligonucleotide array CGH. Genes Chromosomes Cancer. 2007;46:1119-1128.
18. Schwarzacher T. DNA, chromosomes, and in situ hybridization. Genome. 2003;46:953-962.
19. Costantini M, Clay O, Federico C, et al. Human chromosomal bands: nested structure, high-definition map and molecular basis. Chromosoma. 2007;116:29-40.
20. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
21. Najfeld V. Diagnostic application of FISH to hematological malignancies. Cancer Invest. 2003;21:807-814.
22. Engle LJ, Simpson CL, Landers JE. Using high- throughput SNP technologies to study cancer. Oncogene. 2006;25:1594-1601.
23. Nannya Y, Sanada M, Nakazaki K, et al. Arobust algorithm for copy number detection using high- density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res. 2005;65:6071-6079.
24. Li X, Self SG, Galipeau PC, Paulson TG, Reid BJ. Direct inference of SNP heterozygosity rates and resolution of LOH detection. PLoS Comput Biol (http://www.ploscompbiol.org/home.action). 2007;3:2398-2407.
25. Tan DS, Lambros MB, Natrajan R, Reis-Filho JS. Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab Invest. 2007;87:737-754.
26. Lamy P, Andersen CL, Wikman FP, Wiuf C. Geno- typing and annotation of Affymetrix SNP arrays. Nucleic Acids Res. (http://nar.oxfordjournals.org) 2006;34:e100.
27. Yamamoto G, Nannya Y, Kato M, et al. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet. 2007;81:114-126.
28. Barrett MT, Scheffer A, Ben-Dor A, et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci USA. 2004;101:17765-17770.
29. Nuwaysir EF, Huang W, Albert TJ, et al. Gene expression analysis using oligonucleotide arrays produced by maskless photolithography. Genome Res. 2002;12:1749-1755.
30. Albert TJ, Norton J, Ott M, et al. Light-directed 5'→3' synthesis of complex oligonucleotide mi- croarrays. Nucleic Acids Res. (http://nar. oxfordjournals.org) 2003;31:e35.
31. Selzer RR, Richmond TA, Pofahl NJ, et al. Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligo- nucleotide array CGH. Genes Chromosomes Cancer. 2005;44:305-319.
32. Gondek LP, Tiu R, O'Keefe CL, et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS- derived AML. Blood. 2008;111:1534-1542.
33. Mohamedali A, Gaken J, Twine NA, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood. 2007;110:3365-3373.
34. Carter NP. Methods and strategies for analyzing copy number variation using DNA microarrays. Nat Genet. 2007;39:S16-S21.
35. Guttman M, Mies C, Dudycz-Sulicz K, et al. Assessing the significance of conserved genomic aberrations using high resolution genomic microarrays. PLoS Genet. 2007;3:1461-1486.
36. Conrad DF, Andrews TD, Carter NP, Hurles ME, Pritchard JK. A high-resolution survey of deletion polymorphism in the human genome. Nat Genet. 2006;38:75-81.
37. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol. 2002;30:229-236.
38. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
39. Raghavan M, Lillington DM, Skoulakis S, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res. 2005;65:375-378.
40. Gondek LP, Dunbar AJ, Szpurka H, McDevitt MA, Maciejewski JP. SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLoS ONE. (http://www.plosone. org) 2007;2:e1225.
41. Fitzgibbon J, Smith LL, Raghavan M, et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leu- kemias. Cancer Res. 2005;65:9152-9154.
42. Flotho C, Kratz CP, Bergstrasser E, et al. Geno- type-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood. 2008;111:966-967.
43. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61:7233-7239.
44. Pfeifer D, Pantic M, Skatulla I, et al. Genome- wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood. 2007;109:1202-1210.
45. Bruce S, Leinonen R, Lindgren CM, et al. Global analysis of uniparental disomy using high density genotyping arrays. J Med Genet. 2005;42:847-851.
46. Kawamata N, Ogawa S, Zimmermann M, et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood. 2008;111:776-784.
47. Kloth JN, Oosting J, van Wetzel T, et al. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer. BMC Genomics. 2007;8:1-13.
48. Zhang ZF, Ruivenkamp C, Staaf J, et al. Detection of submicroscopic constitutional chromosome aberrations in clinical diagnostics: a validation of the practical performance of different array platforms. Eur J Hum Genet. 2008;16:786-792.
49. Babicz M, Kowalczyk JR, Winnicka D, et al. The effectiveness of high-resolution-comparative genomic hybridization in detecting the most common chromosomal abnormalities in pediatric myelodysplastic syndromes. Cancer Genet Cytogenet. 2005;158:49-54.
50. Kim MH, Stewart J, Devlin C, et al. The application of comparative genomic hybridization as an additional tool in the chromosome analysis of acute myeloid leukemia and myelodysplastic syndromes. Cancer Genet Cytogenet. 2001;126:26- 33.
51. Castuma MV, Rao PH, Acevedo SH, Larripa IB. Comparative genomic hybridization study of de novo myeloid neoplasia 1. Acta Haematol. 2000; 104:25-30.
52. Wilkens L, Burkhardt D, Tchinda J, et al. Cytogenetic aberrations in myelodysplastic syndrome detected by comparative genomic hybridization and fluorescence in situ hybridization. Diagn Mol Pathol. 1999;8:47-53.
53. Paulsson K, Heidenblad M, Strombeck B, et al. High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. Leukemia. 2006;20:840-846.
54. Suela J, Alvarez S, Cigudosa JC. DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes. Cytogenet Genome Res. 2007;118:304-309.
55. Inazawa J, Inoue J, Imoto I. Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci. 2004;95:559-563.
56. Mantripragada KK, Buckley PG, de Stahl TD, Dumanski JP. Genomic microarrays in the spotlight. Trends Genet. 2004;20:87-94.
57. O'Keefe CL, Tiu R, Gondek LP, et al. High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. Exp Hematol. 2007;35:240-251.
58. Hosoya N, Sanada M, Nannya Y, et al. Genome- wide screening of DNA copy number changes in chronic myelogenous leukemia with the use of high-resolution array-based comparative genomic hybridization. Genes Chromosomes Cancer. 2006;45:482-494.
59. Gondek LP, Haddad AS, O'Keefe CL, et al. Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. Exp Hematol. 2007;35:1728-1738.
60. Mori N, Morosetti R, Mizoguchi H, Koeffler HP. Progression of myelodysplastic syndrome: allelic loss on chromosomal arm 1p. Br J Haematol. 2003;122:226-230.
61. Tyybakinoja A, Saarinen-Pihkala U, Elonen E, Knuutila S. Amplified, lost, and fused genes in 11q23-25 amplicon in acute myeloid leukemia, an array-CGH study. Genes Chromosomes Cancer. 2006;45:257-264.
62. Tyybakinoja A, Elonen E, Piippo K, Porkka K, Knuutila S. Oligonucleotide array-CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid leukemia. Leukemia. 2007;21:571-574.
63. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F- positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007;110:375-379.
64. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome- negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370-3373.
65. Nishii K, Nanbu R, Lorenzo VF, et al. Expression of the JAK2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-de- rived leukemia of megakaryoblastic nature. Leukemia. 2007;21:1337-1338.
66. Illmer T, Schaich M, Ehninger G, Thiede C. Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias. Haematologica. 2007;92:137-138.
67. Paulsson K, Heidenblad M, Morse H, et al. Identification of cryptic aberrations and characterization of translocation breakpoints using array CGH in high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia. 2006;20:2002-2007.
68. Tsukasaki K, Lohr D, Sugahara K, et al. Comparative genomic hybridization analysis of Japanese B-cell chronic lymphocytic leukemia: correlation with clinical course. Leuk Lymphoma. 2006;47:261-266.
69. Usvasalo A, Savola S, Raty R, et al. CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults-An array CGH study. Leuk Res. 2008;32:1228-1235.
70. Steinemann D, Cario G, Stanulla M, et al. Copy number alterations in childhood acute lymphoblastic leukemia and their association with minimal residual disease. Genes Chromosomes Cancer. 2008;47:471-480.
71. Kuchinskaya E, Nordgren A, Heyman M, et al. Tiling-resolution array-CGH reveals the pattern of DNAcopy number alterations in acute lymphoblastic leukemia with 21q amplification: the result of telomere dysfunction and breakage/fusion/ breakage cycles? Leukemia. 2007;21:1327-1330.
72. Strefford JC, van Delft FW, Robinson HM, et al. Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Proc Natl Acad Sci USA. 2006;103:8167-8172.
73. Kuchinskaya E, Heyman M, Nordgren A, et al. Array-CGH reveals hidden gene dose changes in children with acute lymphoblastic leukaemia and a normal or failed karyotype by G-banding. Br J Haematol. 2008;140:572-577.
74. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758-764.
75. Lilljebjorn H, Heidenblad M, Nilsson B, et al. Combined high-resolution array-based comparative genomic hybridization and expression profiling of ETV6/RUNX1-positive acute lymphoblastic leukemias reveal a high incidence of cryptic Xq duplications and identify several putative target genes within the commonly gained region. Leukemia. 2007;21:2137-2144.
76. Tyybakinoja A, Vilpo J, Knuutila S. High-resolution oligonucleotide array-CGH pinpoints genes involved in cryptic losses in chronic lymphocytic leukemia. Cytogenet Genome Res. 2007;118:8-12.
77. Lehmann S, Ogawa S, Raynaud SD, et al. Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia. Cancer. 2008;112:1296-1305.
78. Walker BA, Leone PE, Jenner MW, et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood. 2006;108:1733-1743.
79. Jenner MW, Leone PE, Walker BA, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007;110:3291-3300.